Covestor’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$0 Sell
11
-7
-39% -$268 ﹤0.01% 2421
2026
Q2
$1K Buy
18
+12
+200% +$388 ﹤0.01% 2086
2026
Q1
$0 Sell
6
-2
-25% -$55 ﹤0.01% 2313
2025
Q4
$0 Sell
8
-2
-20% -$53 ﹤0.01% 2311
2025
Q3
$0 Buy
10
+5
+100% +$116 ﹤0.01% 2331
2025
Q2
$0 Sell
5
-4
-44% -$78 ﹤0.01% 2264
2025
Q1
$0 Buy
9
+3
+50% +$67 ﹤0.01% 2275
2024
Q4
$0 Buy
6
+3
+100% +$82 ﹤0.01% 2282
2024
Q3
$0 Hold
3
– – ﹤0.01% 2273
2024
Q2
$0 Sell
3
-7
-70% -$264 ﹤0.01% 2283
2024
Q1
$0 Buy
10
+5
+100% +$205 ﹤0.01% 2284
2023
Q4
$0 Hold
5
– – ﹤0.01% 2191
2023
Q3
$0 Hold
5
– – ﹤0.01% 2162
2023
Q2
$0 Hold
5
– – ﹤0.01% 2176
2023
Q1
$0 Hold
5
– – ﹤0.01% 2074
2022
Q4
$0 Hold
5
– – ﹤0.01% 2111
2022
Q3
$0 Sell
5
-1
-17% -$31 ﹤0.01% 2051
2022
Q2
$0 Sell
6
-2
-25% -$58 ﹤0.01% 1960
2022
Q1
$0 Sell
8
-2
-20% -$64 ﹤0.01% 2143
2021
Q4
$0 Buy
+10
New +$436 ﹤0.01% 2136

Other funds holding CLDX

Covestor's CLDX Position: Q3 2026 in Review

Covestor reduced its Celldex Therapeutics (CLDX) stake by 39% in Q3 2026, selling an estimated $268 and leaving 11 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2421.

Covestor first reported a position in CLDX in Q4 2021 and has held it in 20 quarters since. The position peaked at $1K in Q2 2026. 166 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Covestor held 11 shares of Celldex Therapeutics worth $0 as of Q3 2026.
  • Covestor sold 7 Celldex Therapeutics shares in Q3 2026, an estimated $268.
  • Celldex Therapeutics made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2421 holding.
  • Covestor first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 20 quarters since.
  • Covestor's Celldex Therapeutics position peaked at $1K in Q2 2026.
  • 166 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.